Date: Wednesday, March 23rd, 2022
Topic: Blast from the Past: New Drugs of 2021 (22.03)
This presentation focused on new therapeutic entities and their potential to disrupt drug spending and/or current clinical practice. Examples included medications for acute and chronic indications, as well as biosimilars and vaccines.
The CPS clinical development process from surveillance to resource delivery was discussed.
• Current areas of focus in new drug approvals
• The financial and clinical impact of drugs recently approved
• Best practices to optimize medication management
Valerie Sheehan, Vice President, Clinical Program Development, CPS
Karen Lee, Vice President, Clinical Program Development, CPS